Emergent BioSolutions (EBS) Set to Announce Quarterly Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) is scheduled to post its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Emergent BioSolutions to post earnings of ($3.65) per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.44). The business had revenue of $276.60 million during the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same period last year, the business posted ($0.31) EPS. On average, analysts expect Emergent BioSolutions to post $-14 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Emergent BioSolutions Price Performance

Shares of EBS traded down $0.04 on Tuesday, reaching $1.86. 221,861 shares of the company’s stock were exchanged, compared to its average volume of 2,560,583. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $10.88. The company has a current ratio of 1.04, a quick ratio of 0.54 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average price of $2.45 and a two-hundred day moving average price of $2.23.

Analyst Ratings Changes

Separately, Benchmark reissued a “buy” rating and issued a $5.00 price target on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.